{"nct_id": "NCT05633667", "age": "Adults", "cancer_center_accrual_goal_upper": 0, "data_table4": "Interventional", "drug_list": {"drug": [{"drug_name": "Drug: Zimberelimab (ZIM)"}, {"drug_name": "Drug: Nab-paclitaxel"}, {"drug_name": "Drug: Pemetrexed"}, {"drug_name": "Drug: Cisplatin"}, {"drug_name": "Drug: Sacituzumab govitecan-hziy (SG)"}, {"drug_name": "Drug: Paclitaxel"}, {"drug_name": "Drug: Docetaxel"}, {"drug_name": "Drug: Etrumadenant (ETRUMA)"}, {"drug_name": "Drug: Domvanalimab (DOM)"}, {"drug_name": "Drug: Carboplatin"}, {"drug_name": "Drug: Nivolumab"}]}, "long_title": "A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)", "management_group_list": {"management_group": [{"is_primary": "Y", "management_group_name": "Group1"}]}, "oncology_group_list": {"oncology_group": [{"group_name": "Group1", "is_primary": "N"}]}, "phase": "PHASE2", "principal_investigator": "Gilead Study Director", "principal_investigator_institution": "Gilead Sciences", "program_area_list": {"program_area": [{"is_primary": "Y", "program_area_name": "Program1"}]}, "protocol_id": 0, "protocol_no": "", "protocol_target_accrual": 593, "protocol_type": "INTERVENTIONAL", "prior_treatment_requirements": ["Key Inclusion Criteria:", "All Substudies:", "* Histologically or cytologically documented non-small-cell lung cancer (NSCLC).", "* No known actionable genomic alterations for which targeted therapies are available.", "* Eastern cooperative oncology group (ECOG) performance status score of 0 or 1.", "* Measurable disease per response evaluation criteria in solid tumors.", "* Adequate hematologic and end-organ function.", "* Individuals of childbearing potential who engage in heterosexual intercourse must agree to use specified method(s) of contraception.", "Substudy 01: All Experimental arms", "* Stage IV NSCLC.", "* For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alteration negative.", "* PD-L1 status by central confirmation.", "* No prior systemic treatment for metastatic NSCLC.", "Substudy 02: All Experimental arms", "* Stage IV NSCLC.", "* In individuals with nonsquamous histology and actionable EGFR, ALK, or other known genomic alterations must have received treatment with at least 1 targeted therapy to the appropriate genomic alteration.", "Substudy 03: All Experimental arms", "* Previously untreated individuals with resectable (Stage II, IIIA, IIIB (T\\[3-4\\]N2) NSCLC (per American Joint Committee on Cancer (AJCC) Edition 8).", "* Planned surgery must comprise of lobectomy, sleeve lobectomy, or bi-lobectomy.", "* PD-L1 status by central confirmation.", "* For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alteration negative.", "Exclude - Key Exclusion Criteria:", "Exclude - All Substudies:", "Exclude - * Mixed small-cell lung cancer and NSCLC histology.", "Exclude - * Active second malignancy.", "Exclude - * Active autoimmune disease.", "Exclude - * History of or current non-infectious pneumonitis/interstitial lung disease.", "Exclude - * Active serious infection within 4 weeks prior to study treatment.", "Exclude - Substudy 01 and 02", "Exclude - * Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.", "Exclude - * Received previous anticancer therapy within 4 weeks prior to enrollment.", "Exclude - Substudy 03: All Experimental arms", "Exclude - * NSCLC previously treated with systemic therapy or radiotherapy.", "Exclude - * Received prior treatment with any anti-PD-(L)-1 or other immune checkpoint inhibitors (CPIs).", "Exclude - Note: Other protocol defined inclusion/exclusion criteria may apply"], "short_title": "Study of Novel Treatment Combinations in Patients With Lung Cancer", "site_list": {"site": []}, "sponsor_list": {"sponsor": [{"is_principal_sponsor": "Y", "sponsor_name": "Gilead Sciences", "sponsor_protocol_no": "", "sponsor_roles": "sponsor"}]}, "staff_list": {"protocol_staff": []}, "status": "open to accrual", "summary": "The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Substudy-01 will compare the different novel combinations versus standard of care in participants with metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC) who have not been treated before. Substudy-02 will compare the different novel combination versus standard of care in participants with cancer that has progressed after receiving previous treatment for metastatic NSCLC. Substudy-03 will compare the different novel combinations versus standard of care in participants with resectable stage II-III NSCLC.\n\nThe primary objectives of this study are:\n\nSubstudy-01 and Substudy-02: To evaluate the objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).\n\nSubstudy-03: To evaluate the efficacy of treatment combinations based on complete pathological response (pCR) rate.", "treatment_list": {"step": [{"arm": [{"arm_code": "Substudy 01: Zimberelimab (ZIM) + Sacituzumab govitecan-hziy (SG) + Domvanalimab (DOM)", "arm_internal_id": 0, "arm_description": "Participants will receive ZIM, SG and DOM until disease progression (PD), unacceptable toxicity, or protocol specified discontinuation criteria are met.", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Zimberelimab (ZIM)", "level_internal_id": 0, "level_suspended": "N"}, {"level_code": "1", "level_description": "Drug: Domvanalimab (DOM)", "level_internal_id": 1, "level_suspended": "N"}, {"level_code": "2", "level_description": "Drug: Sacituzumab govitecan-hziy (SG)", "level_internal_id": 2, "level_suspended": "N"}]}, {"arm_code": "Substudy 01: ZIM + DOM + Etrumadenant (ETRUMA)", "arm_internal_id": 1, "arm_description": "Participants will receive ZIM, DOM and ETRUMA until PD, unacceptable toxicity, or protocol specified discontinuation criteria are met.", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Zimberelimab (ZIM)", "level_internal_id": 0, "level_suspended": "N"}, {"level_code": "1", "level_description": "Drug: Domvanalimab (DOM)", "level_internal_id": 1, "level_suspended": "N"}, {"level_code": "2", "level_description": "Drug: Etrumadenant (ETRUMA)", "level_internal_id": 2, "level_suspended": "N"}]}, {"arm_code": "Substudy 01: ZIM + ETRUMA", "arm_internal_id": 2, "arm_description": "Participants will receive ZIM and ETRUMA until PD, unacceptable toxicity, or protocol specified discontinuation criteria are met.", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Zimberelimab (ZIM)", "level_internal_id": 0, "level_suspended": "N"}, {"level_code": "1", "level_description": "Drug: Etrumadenant (ETRUMA)", "level_internal_id": 1, "level_suspended": "N"}]}, {"arm_code": "Substudy 01: Zimberelimab (ZIM) + Sacituzumab govitecan-hziy (SG)", "arm_internal_id": 3, "arm_description": "Participants will receive ZIM and SG until disease progression (PD), unacceptable toxicity, or protocol specified discontinuation criteria are met.", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Zimberelimab (ZIM)", "level_internal_id": 0, "level_suspended": "N"}, {"level_code": "1", "level_description": "Drug: Sacituzumab govitecan-hziy (SG)", "level_internal_id": 1, "level_suspended": "N"}]}, {"arm_code": "Substudy 01: ZIM + Platinum Based Chemotherapy", "arm_internal_id": 4, "arm_description": "Expansion Stage Only: Participants will receive ZIM plus any one of the chemotherapy (choice of chemotherapy is dependent on histology).\n\nPlatinum Based Chemotherapy will be cisplatin or carboplatin and pemetrexed (non-squamous histology) or carboplatin, paclitaxel and nabpaclitaxel (squamous histology).", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Zimberelimab (ZIM)", "level_internal_id": 0, "level_suspended": "N"}, {"level_code": "1", "level_description": "Drug: Carboplatin", "level_internal_id": 1, "level_suspended": "N"}, {"level_code": "2", "level_description": "Drug: Cisplatin", "level_internal_id": 2, "level_suspended": "N"}, {"level_code": "3", "level_description": "Drug: Pemetrexed", "level_internal_id": 3, "level_suspended": "N"}, {"level_code": "4", "level_description": "Drug: Paclitaxel", "level_internal_id": 4, "level_suspended": "N"}, {"level_code": "5", "level_description": "Drug: Nab-paclitaxel", "level_internal_id": 5, "level_suspended": "N"}]}, {"arm_code": "Substudy 02: SG + ZIM + ETRUMA", "arm_internal_id": 5, "arm_description": "Participants will receive SG, ZIM and ETRUMA until PD, unacceptable toxicity, or protocol specified discontinuation criteria are met.", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Zimberelimab (ZIM)", "level_internal_id": 0, "level_suspended": "N"}, {"level_code": "1", "level_description": "Drug: Sacituzumab govitecan-hziy (SG)", "level_internal_id": 1, "level_suspended": "N"}, {"level_code": "2", "level_description": "Drug: Etrumadenant (ETRUMA)", "level_internal_id": 2, "level_suspended": "N"}]}, {"arm_code": "Substudy 02: Either Docetaxel or SG (Monotherapy Only)", "arm_internal_id": 6, "arm_description": "Participants will receive either Docetaxel or SG until PD, unacceptable toxicity, or protocol specified discontinuation criteria are met.", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Sacituzumab govitecan-hziy (SG)", "level_internal_id": 0, "level_suspended": "N"}, {"level_code": "1", "level_description": "Drug: Docetaxel", "level_internal_id": 1, "level_suspended": "N"}]}, {"arm_code": "Substudy 03 - ZIM + DOM + Platinum-based Chemotherapy", "arm_internal_id": 7, "arm_description": "Participants will receive ZIM plus DOM and any one of the chemotherapy (choice of chemotherapy is dependent on histology).\n\nPlatinum Based Chemotherapy will be carboplatin and pemetrexed (non-squamous histology) or carboplatin and paclitaxel (squamous histology).", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Zimberelimab (ZIM)", "level_internal_id": 0, "level_suspended": "N"}, {"level_code": "1", "level_description": "Drug: Domvanalimab (DOM)", "level_internal_id": 1, "level_suspended": "N"}, {"level_code": "2", "level_description": "Drug: Carboplatin", "level_internal_id": 2, "level_suspended": "N"}, {"level_code": "3", "level_description": "Drug: Pemetrexed", "level_internal_id": 3, "level_suspended": "N"}, {"level_code": "4", "level_description": "Drug: Paclitaxel", "level_internal_id": 4, "level_suspended": "N"}]}, {"arm_code": "Substudy 03 - ZIM + Platinum-based Chemotherapy", "arm_internal_id": 8, "arm_description": "Participants will receive ZIM plus any one of the chemotherapy (choice of chemotherapy is dependent on histology).\n\nPlatinum Based Chemotherapy will be carboplatin and pemetrexed (non-squamous histology) or carboplatin and paclitaxel (squamous histology).", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Zimberelimab (ZIM)", "level_internal_id": 0, "level_suspended": "N"}, {"level_code": "1", "level_description": "Drug: Carboplatin", "level_internal_id": 1, "level_suspended": "N"}, {"level_code": "2", "level_description": "Drug: Pemetrexed", "level_internal_id": 2, "level_suspended": "N"}, {"level_code": "3", "level_description": "Drug: Paclitaxel", "level_internal_id": 3, "level_suspended": "N"}]}, {"arm_code": "Substudy 03: Nivolumab + Platinum-based Chemotherapy", "arm_internal_id": 9, "arm_description": "Participants will receive nivolumab plus any one of the chemotherapy (choice of chemotherapy is dependent on histology).\n\nPlatinum Based Chemotherapy will be carboplatin and pemetrexed (non-squamous histology) or carboplatin and paclitaxel (squamous histology).", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Carboplatin", "level_internal_id": 0, "level_suspended": "N"}, {"level_code": "1", "level_description": "Drug: Pemetrexed", "level_internal_id": 1, "level_suspended": "N"}, {"level_code": "2", "level_description": "Drug: Paclitaxel", "level_internal_id": 2, "level_suspended": "N"}, {"level_code": "3", "level_description": "Drug: Nivolumab", "level_internal_id": 3, "level_suspended": "N"}]}], "match": [{"and": [{"clinical": {"oncotree_primary_diagnosis": "", "disease_status": ["", ""]}}, {"genomic": {"hugo_symbol": "", "variant_category": ""}}]}]}]}}